All In Biotech

Drug Trial Radar · NCT04508621

A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia

Last checked: Nov 20, 2026Latest source record: Dec 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 514 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

514

Actual

Start

Jul 22, 2020

Primary completion

Nov 1, 2021

Study completion Nov 1, 2021

Sponsor

Lead sponsor
Tonix Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

  • TNX-102 SLDrug

    Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.

  • Placebo SL TabletDrug

    Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patient will have the dose increased to 2 tablets for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores.Time frame: 14 weeks

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • Tonix Clinical Site

    Birmingham, Alabama

  • Tonix Clinical Site

    Phoenix, Arizona

  • Tonix Clinical Site

    Oceanside, California

  • Tonix Clinical Site

    San Diego, California

  • Tonix Clinical Site

    Santa Ana, California

  • Tonix Clinical Site

    Temecula, California

  • Tonix Clinical Site

    Cromwell, Connecticut

  • Tonix Clinical Site

    Fort Myers, Florida

  • Tonix Clinical Site

    Jacksonville, Florida

  • Tonix Clinical Site

    North Miami, Florida

  • Tonix Clinical Site

    Ocala, Florida

  • Tonix Clinical Site

    Orlando, Florida

  • Tonix Clinical Site

    Alpharetta, Georgia

  • Tonix Clinical Site

    Evansville, Indiana

  • Tonix Clinical Site

    West Des Moines, Iowa

  • Tonix Clinical Site

    Prairie Village, Kansas

  • Tonix Clinical Site

    New Orleans, Louisiana

  • Tonix Clinical Site

    Boston, Massachusetts

  • Tonix Clinical Site

    Albuquerque, New Mexico

  • Tonix Clinical Site

    Williamsville, New York

  • Tonix Clinical Site

    High Point, North Carolina

  • Tonix Clinical Site

    Raleigh, North Carolina

  • Tonix Clinical Site

    Cincinnati, Ohio

  • Tonix Clinical Site

    Dayton, Ohio

  • Tonix Clinical Site

    North Canton, Ohio

  • Tonix Clinical Site

    Oklahoma City, Oklahoma

  • Tonix Clinical Site

    Tulsa, Oklahoma

  • Tonix Clinical Site

    Portland, Oregon

  • Tonix Clinical Site

    Warwick, Rhode Island

  • Tonix Clinical Site

    Chattanooga, Tennessee

  • Tonix Clinical Site

    Memphis, Tennessee

  • Tonix Clinical Site

    Austin, Texas

  • Tonix Clinical Site

    Dallas, Texas

  • Tonix Clinical Site

    Salt Lake City, Utah

  • Tonix Clinical Site

    Charlottesville, Virginia

  • Tonix Clinical Site

    Kenosha, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.